拜玛林制药 BMRN 深 沪
已收盘 08-01 16:00:00 美东时间
58.14
+0.290
+0.50%
华盛通- 最 高58.19
- 今 开57.50
- 成交量 381.75万股
- 最 低 56.52
- 昨 收 57.85
- 总市值 111.63亿
- 52周最高 94.85
- 市盈率 静 26.34
- 换手率 1.99%
- 52周最低 52.93
- 委 比 -75.07%
- 总股本 1.92亿
- 历史最高 151.75
- 量 比 2.20
- 振 幅 2.89%
- 历史最低 23.735
- 每 手 1
- 风险率 9.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多What's Next: Biomarin Pharmaceutical's Earnings Preview
Biomarin Pharmaceutical (NASDAQ:BMRN) will release its quarterly earnings repor...
08-01 23:04
Sephience Gets FDA Approval, Now A Key Revenue Driver For PTC Therapeutics
PTC Therapeutics secures FDA approval for Sephience in PKU, launching August with analysts projecting strong revenue and broad patient impact.
07-30 01:58
Biomea Fusion Appoints Julianne Averill to its Board of Directors
Biomea Fusion, Inc. has appointed Julianne Averill to its Board of Directors and the Audit Committee, effective July 22, 2025, succeeding Bihua Chen. Averill, a seasoned finance and strategy executive, brings over two decades of experience in life sciences and digital health. She currently serves as Managing Director at Danforth Advisors and specializes in capital markets, M&A, and organizational design. Averill holds an M.S. in Accountancy and i...
07-24 11:00
Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $96
Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $97 to $96.
07-22 20:49
美股大行评级 | 潜在涨幅94.06%！摩根大通上调BioMarin制药目标价至113美元，维持"超配"评级
今日重点评级关注：摩根大通：维持BioMarin Pharmaceutical"超配"评级，目标价从108美元升至113美元；Oppenheimer：维持P10"跑赢大市"评级，目标价从20美元升至21美元
07-15 09:23
JP Morgan Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $113
JP Morgan analyst Jessica Fye maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $108 to $113.
07-14 23:59
BioMarin Pharma Presents New Data Underscoring Long-Term Efficacy And Safety Of ROCTAVIAN At Congress Of ISTH
Data from longest and largest hemophilia gene therapy study demonstrates sustained factor VIII expression and bleed control, with 81.3% of individuals remaining off prophylaxisNo new safety signals observedSAN RAFAEL,
06-24 21:05
Biomea Fusion Announces Proposed Public Offering of Securities
Biomea Fusion, Inc. has launched an underwritten public offering of its common stock and warrants. The offering includes the option for underwriters to purchase up to 15% more shares. The company plans to raise funds to support its diabetes and obesity treatments, icovamenib and BMF-650. The offering is expected to close on June 20, 2025, subject to market conditions. Jefferies is acting as sole book running manager.
06-17 20:33
Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs
Jim Cramer recommends Union Pacific but is "getting tired of the orphan drug model." Here's what the "Mad Money" host said.
06-12 20:05
